All In Biotech

NDA 050655 · Baxter Hlthcare

Nallpen In Plastic Container

Nafcillin Sodium · Injection

Last checked: Nov 19, 2026Latest source record: Apr 5, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Oct 31, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

17

3 Phase 3, 2 recruiting

FAERS reports

710

618 serious, 98 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 6, 2024.

INDICATIONS AND USAGE Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY - Susceptibility Test Methods ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to methicillin-resistant Staphylococcus species, therapy with Nafcillin Injection, USP should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin Injection, USP and other antibacterial drugs, Nafcillin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 31, 1989 Original approval · Type 3 - New Dosage Form
2 products under this application
  • NALLPEN IN PLASTIC CONTAINER · NAFCILLIN SODIUM EQ 2GM BASE/100ML · INJECTABLE, INJECTION · Prescription
  • NALLPEN IN PLASTIC CONTAINER · NAFCILLIN SODIUM EQ 20MG BASE/ML · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Nafcillin" as an intervention, any sponsor and status, largest first.

All 17 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective52
  • acute kidney injury48
  • rash44
  • tubulointerstitial nephritis39
  • hypokalaemia38
  • renal failure35
  • renal failure acute35
  • pyrexia34
  • drug interaction32
  • anxiety25
  • drug hypersensitivity25
  • nephropathy toxic24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200511
200610
200915
201034
201133
201244
201336
201456
201535
201635
201746
201842
201959
202058
202141
202248
202340
202418
202522
202620

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 36 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.